Bioventure is a UAE-based biopharmaceutical company focused on biotech and pharmaceutical activities, including the distribution and commercialization of biosimilars and targeted generic pharmaceuticals in the Middle East and Africa.

Bioventure

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Róbert Wessman

Alvotech

Sahara Pharmaceutical is a distributor of pharmaceutical products and medical supplies, working as a distributor for GULF INJECT under the Julphar Group since 1994.

Sahara Pharmaceutical

Bioventure  | 4,635 followers on LinkedIn. UAE based biopharmaceutical company focused on biotech and generics commercialization, tech transfer, in/out-licensing | Bioventure FZ-LLC (“BV”) is a UAE-based biopharmaceutical company with a global network, focused on Biotech and a wide range of pharmaceutical activities, delivering world-class solutions within the UAE and the Middle East.

BV specializes in Biotech and Generics Commercialization, Tech Transfer and In/Out-licensing activities. BV currently holds an equity stake in Alvotech and agreement for an exclusive distribution and commercialization of Alvotech’s biosimilar portfolio across the Middle East and Africa.

CEO Geltec Healthcare FZCO, UAE

Mahmoud Heikal

Financial Controller/ Head of Finance

Qaim Mehdi, ACA, ACCA

Licensing Biosimilars and Generics | Alliance Management | Portfolio Management

Shreya Jain

Head Of Quality Control at Bioventure healthcare a Yash holdings subsidiary

Mohammad Nayim Ansari

On World Hypertension Day, it is crucial to highlight the pressing need for global action against hypertension - a leading risk factor of cardiovascular diseases, with more than one billion individuals affected worldwide. Join us at GlobalOne Healthcare Holding , in supporting initiatives that help improve detection and management of hypertension, ultimately saving lives. Yas Holding #GlobalOneHealthcareHolding #Bioventure #YasHolding #care #health

Yas Holding Healthcare

🚀 Exciting Times Ahead in Pharma: Exploring the Intersection of Pharmaceuticals and AI! 🧪💻 Is it time for pharmaceutical professionals to start diving into the realm of AI? 🤔 Are there ample use cases waiting to be discovered in Pharma? 🧐 To find out, I've embarked on a fascinating journey by joining an insightful course at Kellogg, alongside wonderful colleagues equally curious about this intersection! 🔍💡 #Pharma #AI #Kellogg #Innovation #FutureOfWork

Bahaa Rashad

Here's to the incredible women who shape our lives with love, strength, and wisdom. Happy Mother's Day! 💐❤️ #Bioventure #MothersDay

On the 20th of March every year, we ask the world to unite to help reduce the burden of oral diseases, which affect individuals, health systems and economies everywhere. Its purpose: to empower people with the knowledge, tools and confidence to secure good oral health. #WorldOralHealthDay #Health #Wellbeing

Celebrating the joy, innocence, and future of our nation on Emirati Children's Day! 🇦🇪✨ #UAE #EmiratiChildrensDay #Wellbeing

Around the globe, people will be coming together to mark World Kidney Day. How will you be celebrating? Let us know! #Bioventure #WorldKidneyDay #Wellbeing #KidneyHealthforAll

This day, the UAE celebrates the loyal doctors, under the directives of the wise leadership, to support the march of national doctors, to praise their achievements, and to emphasize the nation's pride in them. Emirati Doctor's Day aims to honor Emirati doctors who regularly prove their efficiency in providing the best treatment services to patients and their dedication to playing their humanitarian role in preserving the health of society members. #EmiratiDoctorsDay #Bioventure #Health #Wellbeing

Welcome the blessings of Ramadan with open hearts and peaceful minds. Ramadan Mubarak! 🌙 #Bioventure #Ramadan2024

Empowered women empower the world. Happy International Women's Day! 💪🌍 #Bioventure #Health #Wellbeing #InternationalWomensDay

Metric
Company Name	Bioventure	Alvotech	Sahara Pharmaceutical
Symbol		ALVO
MSH ID	AE:BIOVENTURE	COM:ALVOTECH	COM:SAHARAMS
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biopharmaceuticals	Drug Manufacturers - Specialty & Generic	Pharmaceutical Distribution
Country	AE	IS	AE
Stage
Employee Count		999
Website	bioventure.ae	alvotech.com	saharams.com
LinkedIn	bioventure-fzc	alvotechpr
Founders

Metric
Market Cap		3.65B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		91.43M
Revenue (LTM)
Revenue (NTM)
Gross Profit		-69.42M
EBITDA		-334.64M
Operating Income		-354.86M
Net Income		-551.73M
EPS		-2.43
Diluted EPS		-2.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-0.15
Operating Profit Margin		-2.13
EBITDA Margin		-3.66
Net Profit Margin		-4.51
Return on Equity		1.01
Return on Assets		-0.47
Return on Capital Employed		2.18

BIOV

AE:BIOVENTURE

Bioventure

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-5.85
P/B Ratio		-5.28
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		63.72
EV Multiple		-7.19

Metric
Days Sales Outstanding		247.94
Days Payables Outstanding		144.34
Days Inventory Outstanding		237.56
Operating Cycle		636.99
Cash Conversion Cycle		501.79
Asset Turnover		0.13

Metric
Operating Cash Flow		-312.19M
Free Cash Flow		-358.66M
Cash Flow to Debt		-0.29
Operating Cash Flow/Sales		-2.26
Free Cash Flow Yield		-0.09

Metric
Cash & Equivalents		11.16M
Accounts Receivable		-8.32M
Inventory		74.43M
Goodwill		12.06M
Debt to Capitalization		7.52
Debt to Assets		1.06
Current Ratio		1.22
Quick Ratio		0.81

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		-0.05
R&D to Revenue		3.24
SG&A to Revenue		1.43